Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug

Biogen and Sage Therapeutics’ race to bring depression drug zuranolone to market is entering the home stretch. After talking to the FDA, the partners have outlined plans to start a rolling submission early in 2022 and complete the filing in the second half of the year.